Irreversible electroporation ablation of end‑stage metastatic retroperitoneal lesions: Report on three cases and literature review

  • Authors:
    • Tian'an Jiang
    • Qiyu Zhao
    • Guo Tian
    • Xinhua Chen
    • Liming Wu
  • View Affiliations

  • Published online on: July 17, 2019     https://doi.org/10.3892/etm.2019.7780
  • Pages: 2243-2249
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Metastatic retroperitoneal tumors constitute an end‑stage disease with poor prognosis that represents a heavy global health burden. The present study aimed to explore the efficacy of irreversible electroporation ablation (IRE) therapy in patients with end‑stage retroperitoneal tumors. Between April 2016 and September 2017, three patients with unresectable retroperitoneal malignant tumors were enrolled. Among these cases, ultrasound (US)‑guided IRE was palliatively performed for targeting 3 tumors (1 tumor per patient) located around the abdominal aorta. Post‑treatment contrast‑enhanced US (CEUS) and contrast‑enhanced computed tomography (CECT) scans were subsequently performed to evaluate the area adjacent to the ablation zone and determine the prognosis. During the follow‑up, the cases experienced a reduction of pain (mean score of 5.8 decreased to 2.2, based on the visual analogue scale), and had an overall survival rate ranging from 2 to 11 months. Case 1 remained alive at the time of submission of this study, but case 2 died within 2 months and case 3 within 11 months due to liver metastases of the primary tumor. At the 3‑week follow‑up, the CEUS image for case 1 exhibited a contrast defect with a sufficient ablation margin, in accordance with the CECT at 1.5 months following IRE, exhibiting complete tumor necrosis without contrast enhancement. Overall, these results suggest that US‑guided percutaneous IRE may be effective in the treatment of end‑stage retroperitoneal tumors. However, further studies are required to substantiate the conclusions of the present study. The present clinical trial was registered at clinicaltrials.gov (ID: NCT02822066) on June 20th, 2016.

References

1 

Macneill AJ, Miceli R, Strauss DC, Bonvalot S, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, et al: Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Trans-Atlantic RPS Working Group. Cancer. 123:1971–1978. 2017. View Article : Google Scholar : PubMed/NCBI

2 

Maurice MJ, Yih JM, Ammori JB and Abouassaly R: Predictors of surgical quality for retroperitoneal sarcoma: Volume matters. J Surg Oncol. 116:766–774. 2017. View Article : Google Scholar : PubMed/NCBI

3 

Mak KS, Phillips JG, Barysauskas CM, Lee LK, Mannarino EG, Van Benthuysen L, Raut CP, Mullen JT, Fairweather M, DeLaney TF and Baldini EH: Acute gastrointestinal toxicity and bowel bag dose-volume parameters for preoperative radiation therapy for retroperitoneal sarcoma. Pract Radiat Oncol. 6:360–366. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Lee HS, Yu JI, Lim DH and Kim SJ: Retroperitoneal liposarcoma: The role of adjuvant radiation therapy and the prognostic factors. Radiat Oncol J. 34:216–222. 2016. View Article : Google Scholar : PubMed/NCBI

5 

Alqasem K, Abukhiran I, Jasser J, Bisharat T, Ellati RT, Khzouz J, Al-Saidi I and Al-Daghamin A: Clinico-pathological outcomes of post-primary and salvage chemotherapy retroperitoneal lymph node dissection for mixed germ cell tumors, King Hussein Cancer Center experience. Turk J Urol. 42:256–260. 2016. View Article : Google Scholar : PubMed/NCBI

6 

Mano R, Becerra MF, Carver BS, Bosl GJ, Motzer RJ, Bajorin DF, Feldman DR and Sheinfeld J: Clinical outcome of patients with Fibrosis/Necrosis at post-chemotherapy retroperitoneal lymph node dissection for advanced germ cell tumors. J Urol. 197:391–397. 2017. View Article : Google Scholar : PubMed/NCBI

7 

Stillström D, Nilsson H, Jesse M, Peterhans M, Jonas E and Freedman J: A new technique for minimally invasive irreversible electroporation of tumors in the head and body of the pancreas. Surgical Endosc. 31:1982–1985. 2017. View Article : Google Scholar

8 

Langan RC, Goldman DA, D'Angelica MI, Dematteo RP, Allen PJ, Balachandran VP, Jarnagin WR and Kingham TP: Recurrence patterns following irreversible electroporation for hepatic malignancies. J Surg Oncol. 115:704–710. 2017. View Article : Google Scholar : PubMed/NCBI

9 

Song ZQ, Xu XH, Pan ZH, Yao CG and Zhou QH: Mechanisms for steep pulse irreversible electroporation technology to kill human large cell lung cancer cells L9981. Int J Clin Exp Med. 7:2386–2394. 2014.PubMed/NCBI

10 

Martin RC, Schwartz E, Adams JA, Farah I and Derhake BM: Intra-operative anesthesia management in patients undergoing surgical irreversible electroporation of the pancreas, Liver, Kidney, and retroperitoneal tumors. Anesth Pain Med. 5:e227862015. View Article : Google Scholar : PubMed/NCBI

11 

Scheltema MJ, Postema AW, de Bruin DM, Buijs M, Engelbrecht MR, Laguna MP, Wijkstra H, de Reijke TM and de la Rosette JJMCH: Irreversible electroporation for the treatment of localized prostate cancer: A summary of imaging findings and treatment feedback. Diagn Interv Radiol. 23:365–370. 2017. View Article : Google Scholar : PubMed/NCBI

12 

Kos B, Voigt P, Miklavcic D and Moche M: Careful treatment planning enables safe ablation of liver tumors adjacent to major blood vessels by percutaneous irreversible electroporation (IRE). Radiol Oncol. 49:234–241. 2015. View Article : Google Scholar : PubMed/NCBI

13 

Chai W, Tian G and Jiang T: Percutaneous irreversible electroporation for portal vein tumor thrombus: A case report. Ultrasound Q. 33:296–299. 2017. View Article : Google Scholar : PubMed/NCBI

14 

Bijur PE, Silver W and Gallagher EJ: Reliability of the visual analog scale for measurement of acute pain. Acad Emerg Med. 8:1153–1157. 2001. View Article : Google Scholar : PubMed/NCBI

15 

Giesinger JM, Kuijpers W, Young T, Tomaszewski KA, Friend E, Zabernigg A, Holzner B and Aaronson NK: Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: Physical functioning, emotional functioning, fatigue and pain. Health Qual Life Outcomes. 14:872016. View Article : Google Scholar : PubMed/NCBI

16 

Dunki-Jacobs EM, Philips P and Martin RC II: Evaluation of thermal injury to liver, pancreas and kidney during irreversible electroporation in an in vivo experimental model. Br J Surg. 101:1113–1121. 2014. View Article : Google Scholar : PubMed/NCBI

17 

Underhill CE, Walsh NJ, Bateson BP, Mentzer C and Kruse EJ: Feasibility and safety of irreversible electroporation in locally advanced pelvic and retroperitoneal tumors. Am Surg. 82:e263–e265. 2016.PubMed/NCBI

18 

Kambakamba P, Bonvini JM, Glenck M, Castrezana López L, Pfammatter T, Clavien PA and DeOliveira ML: Intraoperative adverse events during irreversible electroporation-a call for caution. Am J Surg. 212:715–721. 2016. View Article : Google Scholar : PubMed/NCBI

19 

Qin Z, Zeng J, Liu G, Long X, Fang G, Li Z, Xu K and Niu L: Irreversible electroporation ablation of an unresectable fibrous sarcoma with 2 electrodes: A case report. Technol Cancer Res Treat. Jan 1–2017.doi: 10.1177/1533034617711530 (Epub ahead of print). View Article : Google Scholar

20 

Meng Z, Garrett CR, Shen Y, Liu L, Yang P, Huo Y, Zhao Q, Spelman AR, Ng CS, Chang DZ and Cohen L: Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: A randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas. Br J Cancer. 107:411–416. 2012. View Article : Google Scholar : PubMed/NCBI

21 

Martin RC II, Kwon D, Chalikonda S, Sellers M, Kotz E, Scoggins CM, McMasters KM and Watkins K: Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: Safety and efficacy. Ann Surg. 262:486–494. 2015. View Article : Google Scholar : PubMed/NCBI

22 

Narayanan G, Hosein PJ, Beulaygue IC, Froud T, Scheffer HJ, Venkat SR, Echenique AM, Hevert EC, Livingstone AS, Rocha-Lima CM, et al: Percutaneous image-guided irreversible electroporation for the treatment of unresectable, locally advanced pancreatic adenocarcinoma. J Vasc Interv Radiol. 28:342–348. 2017. View Article : Google Scholar : PubMed/NCBI

23 

Ansari D, Kristoffersson S, Andersson R and Bergenfeldt M: The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: A systematic review of safety and efficacy. Scand J Gastroenterol. 52:1165–1171. 2017. View Article : Google Scholar : PubMed/NCBI

24 

Lee EW, Thai S and Kee ST: Irreversible electroporation: A novel image-guided cancer therapy. Gut Liver. 4 (Suppl 1):S99–S104. 2010. View Article : Google Scholar : PubMed/NCBI

25 

Bulvik BE, Rozenblum N, Gourevich S, Ahmed M, Andriyanov AV, Galun E and Goldberg SN: Irreversible electroporation versus radiofrequency ablation: A comparison of local and systemic effects in a Small-animal model. Radiology. 280:413–424. 2016. View Article : Google Scholar : PubMed/NCBI

26 

Distelmaier M, Barabasch A, Heil P, Kraemer NA, Isfort P, Keil S, Kuhl CK and Bruners P: Midterm safety and efficacy of irreversible electroporation of malignant liver tumors located close to major portal or hepatic veins. Radiology. 285:1023–1031. 2017. View Article : Google Scholar : PubMed/NCBI

27 

Schwarze JE, Jeria R, Crosby J, Villa S, Ortega C and Pommer R: Is there a reason to perform ICSI in the absence of male factor? Lessons from the latin american registry of ART. Hum Reprod Open. 2017:hox0132017. View Article : Google Scholar : PubMed/NCBI

28 

Joong Choi C, Roh YH, Kim MC, Choi HJ, Kim YH and Jung GJ: Single-port laparoscopic cholecystectomy for gall bladder polyps. JSLS. 19(pii): e2014.00183. 2015.PubMed/NCBI

29 

Pirracchio R, Sprung CL, Payen D and Chevret S: Utility of time-dependent inverse-probability-of-treatment weights to analyze observational cohorts in the intensive care unit. J Clin Epidemiol. 64:1373–1382. 2011. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Jiang, T., Zhao, Q., Tian, G., Chen, X., & Wu, L. (2019). Irreversible electroporation ablation of end‑stage metastatic retroperitoneal lesions: Report on three cases and literature review. Experimental and Therapeutic Medicine, 18, 2243-2249. https://doi.org/10.3892/etm.2019.7780
MLA
Jiang, T., Zhao, Q., Tian, G., Chen, X., Wu, L."Irreversible electroporation ablation of end‑stage metastatic retroperitoneal lesions: Report on three cases and literature review". Experimental and Therapeutic Medicine 18.3 (2019): 2243-2249.
Chicago
Jiang, T., Zhao, Q., Tian, G., Chen, X., Wu, L."Irreversible electroporation ablation of end‑stage metastatic retroperitoneal lesions: Report on three cases and literature review". Experimental and Therapeutic Medicine 18, no. 3 (2019): 2243-2249. https://doi.org/10.3892/etm.2019.7780